Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Charles M. Rudin,Mark M. Awad,Alejandro Navarro,Maya Gottfried,Solange Peters,Tibor Csőszi,Parneet K. Cheema,Delvys Rodriguez Abreu,Mirjana Wollner,James Chih-Hsin Yang,Julien Mazieres,Francisco Jorquera Orlandi,A. Luft,Mahmut Gumus,Terufumi Kato,Gregory P. Kalemkerian,Yiwen Luo,Victoria Ebiana,M. Catherine Pietanza,Hye Ryun Kim

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

2020

PURPOSEPembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus e...

Keywords:

double blind
Oncology
Lung cancer
first line therapy
Extensive-stage small cell lung cancer
Pathology
Pembrolizumab
Internal medicine
antitumor activity
Placebo
Medicine
Etoposide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

112

Citations